## CENTER FOR DRUG EVALUATION AND RESEARCH

**APPLICATION NUMBER: 20-280/S-031** 

## **CHEMISTRY REVIEW(S)**

| CHEMIST'S REVIEW   |   |  |                   |
|--|---|--|-------------------|
| ORGANIZATION CDER/HFD-510     Division of Metabolism and Endocrine Drug Products   |   | 2. NDA # 20280   |                   |
| 3. NAME AND ADDRESS OF APPLICANT Pharmacia & Upjohn Company 7000, Portage road, Kalamazoo, MI 49001, Phone: ((616) 833-6717  |   | 4. SUPPLEMENT: SE1-031 Doc. Date: Rec. date: 25th-Jan-2001 26th-Jan-2001 |                   |
|  |   | 5. NAME OF THE DRUG: Genotropin  |                   |
|  |   | 6. Nonproprietary Name : Somatropin[rDNA] for Injection                  |                   |
| 7. SUPPLEMENT PROVIDES for long term treatment of growth failure in children born small for gestational age(SGA)   |   | 8. AMEND   | MENT -N/A         |
| 9. PHARMACOLOGICAL CATEGORY Growth hormone replacement therapy in adults and long term treatment of children who have growth failure.  | 10. HOW DISPER  | NSED   | 11. RELATED -N. A |
| 12. DOSAGE FORM: subcutaneous injection  | 13. POTENCY: 1.3 mg/mL(4 IU/mL), 5.0 mg/mL (15 IU/m), 12 mg/mL (36 IU/mL) |  |                   |
| 14. CHEMICAL NAME AND STRUCTURE  Genotropin(Somatropin [rDNA] origin   |   |  |                   |
| 15. COMMENTS: This NDA #20280 supplement 031 is an efficacy supplement. The sponsor has originally submitted this supplement on 30 <sup>th</sup> June 2000, which was withdrawn, based on clinical issues. This is a resubmission. |   |  |                   |
| 16. CONCLUSIONS AND RECOMMENDATIONS The information provided by the sponsor has been reviewed. The sponsor has claimed a categorical exclusion from environmental assessment requirement. SATISFACTORY                             |   |  |                   |
| 17. REVIEWER NAME (AND SIGNATURE)  Pardha Komanduri  DATE COMPLETED: 16th-JULY-2001  |   |  |                   |
| R/D INITIALED BY  DISTRIBUTION: Original NDA 20280 cc. HED-\$10 Division File/ Moore \$/ King C/Pardha K   |   |  |                   |

AP

## APPEARS THIS WAY ON ORIGINAL

## ITEM 3.3 CHEMISTRY, MANUFACTURING, AND CONTROLS SUMMARY

GENOTROPIN® (somatropin [rDNA origin] for injection) is manufactured in Stockholm, Sweden. GENOTROPIN is approved in the following presentations:

- Two-chamber cartridges at strengths of 1.5 mg (without preservative), 5.8 mg (with preservative), and 13.8 mg (with preservative).
- GENOTROPIN MINIQUICK® Growth Hormone Deliver Device containing a 2-chamber cartridge of GENOTROPIN (without preservative) at strengths of 0.2, 0.4, 0.6, 0.8, 1.0, 1.2, 1.4, 1.6, 1.8, and 2.0 mg.

A complete summary of the chemistry, manufacturing, and controls (CMC) of somatropin was included in NDA 20-280.

APPEARS THIS WAY

APPEARS THIS WAY ON ORIGINAL